Naloxone therapy for prescription and illicit opioid poisoning cases aged 50 + in the national poison data system, 2015–2020

References

• National Institute on Drug Abuse. Drugfacts: naloxone drugfacts. 2021. https://www.drugabuse.gov/download/23417/naloxone-drugfacts.pdf?v=8b748408194dff241c227cf6c7c9d04e.
   Google Scholar
• Geiger C, Smart R, Stein BD. Who receives naloxone from emergency medical services? Characteristics of calls and recent trends. Subst Abus. 2020;41(3):400–407.
   PubMed Web of Science ®Google Scholar
• Rege SV, Ngo DA, Ait-Daoud N, et al. Trends and characteristics of naloxone therapy reported to US poison centers. Addiction. 2018;113(12):2309–2315.
   PubMed Web of Science ®Google Scholar
• Sumner SA, Mercado-Crespo MC, Spelke MB, et al. Use of naloxone by emergency medical services during opioid drug overdose resuscitation efforts. Prehosp Emerg Care. 2016; 20(2):220–225.
   PubMed Web of Science ®Google Scholar
• Kispert D, Carwile JL, Silvia KB, et al. Differences in naloxone prescribing by patient age, ethnicity, and clinic location among patients at high-risk of opioid overdose. J Gen Intern Med. 2020;35(5):1603–1605.
   PubMed Web of Science ®Google Scholar
• Schieber LZ, Guy GP, Jr, Seth P, et al. Variation in adult outpatient opioid prescription dispensing by age and sex - United States, 2008-2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):298–302.
   PubMed Web of Science ®Google Scholar
• Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of Long-Term Opioid Use - United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(10):265–269.
   PubMedGoogle Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic Pain-United States, 2016. JAMA. 2016;315(15):1624–1645.
   PubMed Web of Science ®Google Scholar
• Office of Inspector General. HHS Data Brief, July 2019. OEI-02-19-00390: Opioid use decreased in Medicare Part D, while medication-assisted treatment increased. 2019. https://oig.hhs.gov/oei/reports/OEI-02-19-00390.pdf.
   Google Scholar
• Ramachandran S, Salkar M, Bentley JP, et al. Patterns of long-term prescription opioid use among older adults in the United States: a study of medicare administrative claims data. Pain Physician. 2021;24(1):31–40.
   PubMed Web of Science ®Google Scholar
• Office of Inspector General. Data snapshot, February 2021. OEI-02-20-00400: Opioid use in Medicare Part D during the onset of the COVID-19 pandemic. 2021. https://oig.hhs.gov/oei/reports/OEI-02-20-00400.pdf.
   Google Scholar
• Lynch A, Arndt S, Acion L. Late- and typical-onset heroin use among older adults seeking treatment for opioid use disorder. Am J Geriatr Psychiatry. 2021;29(5):417–425.
   PubMed Web of Science ®Google Scholar
• Carroll JJ, Marshall BDL, Rich JD, et al. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: a mixed methods study. Int J Drug Policy. 2017;46:136–145.
   PubMed Web of Science ®Google Scholar
• Kiyatkin EA. Respiratory depression and brain hypoxia induced by opioid drugs: Morphine, oxycodone, heroin, and fentanyl. Neuropharmacology. 2019;151:219–226.
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Whittington RA, et al. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology. 2008;33(5):1179–1191.
   PubMed Web of Science ®Google Scholar
• Gazelka HM, Leal JC, Lapid MI, et al. Opioids in older adults: Indications, prescribing, complications, and alternative therapies for primary care. Mayo Clin Proc. 2020;95(4):793–800.
   PubMed Web of Science ®Google Scholar
• Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual report of the american association of poison control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol. 2020;58(12):1360–1541.
   PubMed Web of Science ®Google Scholar
• Behar E, Rowe C, Santos GM, et al. Acceptability of naloxone co-prescription among primary care providers treating patients on long-term opioid therapy for pain. J Gen Intern Med. 2017;32(3):291–295.
   PubMed Web of Science ®Google Scholar
• Mueller SR, Koester S, Glanz JM, et al. Attitudes toward naloxone prescribing in clinical settings: a qualitative study of patients prescribed high dose opioids for chronic non-cancer pain. J Gen Intern Med. 2017;32(3):277–283.
   PubMed Web of Science ®Google Scholar
• Stein BD, Smart R, Jones CM, et al. Individual and community factors associated with naloxone co-prescribing among long-term opioid patients: a retrospective analysis. J Gen Intern Med. 2021 [cited 17 Feb]. doi: 10.1007/s11606-020-06577-5
   Web of Science ®Google Scholar
• Roberts AW, Look KA, Trull G, et al. Medicaid prescription limits and their implications for naloxone accessibility. Drug Alcohol Depend. 2021;218:108355.
   PubMed Web of Science ®Google Scholar
• Green TC, Davis C, Xuan Z, et al. Laws mandating coprescription of naloxone and their impact on naloxone prescription in five US states, 2014–2018. Am J Public Health. 2020;110(6):881–887.
   PubMed Web of Science ®Google Scholar
• Glober N, Mohler G, Huynh P, et al. Impact of COVID-19 pandemic on drug overdoses in indianapolis. J Urban Health. 2020;97(6):802–807.
   PubMed Web of Science ®Google Scholar
• Mason M, Welch SB, Arunkumar P, et al. Notes from the field: Opioid overdose deaths before, during, and after an 11-week COVID-19 stay-at-home order - Cook County, Illinois, January 1, 2018-October 6, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(10):362–363.
   PubMed Web of Science ®Google Scholar
• Cone DC, Bogucki S, Burns K, et al. Naloxone use by emergency medical services during the COVID-19 pandemic: a national survey. J Addict Med. 2020;14(6):e369–e371.
   PubMed Web of Science ®Google Scholar
• Glenn MJ, Rice AD, Primeau K, et al. Refusals after prehospital administration of naloxone during the COVID-19 pandemic. Prehosp Emerg Care. 2021;25(1):46–54.
   PubMed Web of Science ®Google Scholar
• Passik SD, Webster L. Opioid analgesics: does potency matter? J Opioid Manag. 2014;10(4):263–275.
   PubMedGoogle Scholar
• Silvasti M, Tarkkila P, Tuominen M, et al. Efficacy and side effects of tramadol versus oxycodone for patient-controlled analgesia after maxillofacial surgery. Eur J Anaesthesiol. 1999;16(12):834–839.
   PubMed Web of Science ®Google Scholar
• World Health Organization19). WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2019. https://www.who.int/publications/i/item/9789241550390.
   Google Scholar
• Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used world health organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287–313.
   PubMedGoogle Scholar
• PaxMemphis. Opioids From Strongest to Weakest. 2019. https://paxmemphis.com/opioids-from-strongest-to-weakest/
   Google Scholar
• Chau DL, Walker V, Pai L, et al. Opiates and elderly: Use and side effects. Clin Interv Aging. 2008;3(2):273–278.
   PubMed Web of Science ®Google Scholar
• Baumgartner JC, Radley DC. The spike in drug overdose deaths during the COVID-19 pandemic and policy options to move forward. 2021. https://www.commonwealthfund.org/blog/2021/spike-drug-overdose-deaths-during-covid-19-pandemic-and-policy-options-move-forward.
   Google Scholar